S993-118

What This Bill Does

The bill creates findings Congress finds the following: Illicit xylazine presents an urgent threat to public health and safety, requires unlawful distribution and penalties relating to xylazine Section 401 of the Controlled Substances Act (21 U.S.C, and requires illicit use and distribution of xylazine It is unlawful for any person to engage in any of the following illicit uses of xylazine: Any use in the human species. It relies on compliance mandates, definition changes, exemptions, and trade restrictions. The main policy areas are Healthcare Consumers, Healthcare, Foreign Policy, and Criminal Justice.

Who Benefits and How

Patients and health care consumers affected by the bill could face lower compliance burdens, Foreign businesses and cross-border trade participants affected by the bill could face lower compliance burdens, and Public beneficiaries or protected communities affected by the clause could face reduced risk.

Who Bears the Burden and How

Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Patients and health care consumers affected by the bill would take on compliance duties, and Public beneficiaries or protected communities affected by the clause could face increased risk.

Key Provisions

• Creates findings Congress finds the following: Illicit xylazine presents an urgent threat to public health and safety.
• Requires unlawful distribution and penalties relating to xylazine Section 401 of the Controlled Substances Act (21 U.S.C.
• Requires illicit use and distribution of xylazine It is unlawful for any person to engage in any of the following illicit uses of xylazine: Any use in the human species.
• Requires report to Congress on xylazine.
• Requires declaration of emerging threat Congress declares illicit xylazine use an emerging drug threat, as defined in section 702 of the Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C....